Male pattern baldness in relation to prostate cancer-specific mortality: A prospective analysis in the NHANES I epidemiologic follow-up study

American Journal of Epidemiology

Volumn 183, Issue 3, 2016, Pages 210-217

  Zhou, Cindy Ke ^a,b   Levine, Paul H ^b   Cleary, Sean D ^b   Hoffman, Heather J ^b   Graubard, Barry I ^a   Cook, Michael B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

cohort; male pattern baldness; prostate cancer mortality

Indexed keywords

ANDROGEN; BASELINE SURVEY; CANCER; CONFIDENCE INTERVAL; EPIDEMIOLOGY; HEALTH RISK; MALE; MORTALITY; PATHOLOGY; PHYSIOLOGY;

ADULT; AGE; AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE TYPE ALOPECIA; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATE CANCER; ALOPECIA; NUTRITION; PROSTATIC NEOPLASMS; UNITED STATES;

ADULT; AGED; ALOPECIA; HUMANS; MALE; MIDDLE AGED; NUTRITION SURVEYS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 84962316305     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwv190     Document Type: Article

References (55)

1. American Cancer Society. Cancer Facts & Figures 2013. Atlanta, GA: American Cancer Society; 2013
2. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006; 11: 1388-1413
3. Eeles RA, Olama AA, Benlloch S., et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013; 45(4): 385-391
4. Loeb S, Bjurlin MA, Nicholson J., et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014; 65(6): 1046-1055
5. Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci. 1951; 53(3): 708-728
6. Lichtenstein P, Holm NV, Verkasalo PK., et al. Environmental and heritable factors in the causation of cancer-Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000; 343(2): 78-85
7. Nyholt DR, Gillespie NA, Heath AC., et al. Genetic basis of male pattern baldness. J Invest Dermatol. 2003; 121(6): 1561-1564
8. Weiss JM, Huang WY, Rinaldi S., et al. Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer. 2008; 122(10): 2345-2350
9. Roddam AW, Allen NE, Appleby P., et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of
10. prospective studies. J Natl Cancer Inst. 2008; 100(3): 170-183
11. Gershman B, Shui IM, Stampfer M., et al. Prediagnostic circulating sex hormones are not associated with mortality for men with prostate cancer. Eur Urol. 2014; 65(4): 683-689
12. Pierorazio PM, Ferrucci L, Kettermann A., et al. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int. 2010; 105(6): 824-829
13. Muller RL, Gerber L, Moreira DM., et al. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol. 2012; 62(5): 757-764
14. Plymate SR, Tenover JS, Bremner WJ. Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J Androl. 1989; 10(5): 366-371
15. Feldman HA, Longcope C, Derby CA., et al. Age trends in the level of serum testosterone and other hormones in middle-Aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002; 87(2): 589-598
16. Amoretti A, Laydner H, Bergfeld W. Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-Analysis. J Am Acad Dermatol. 2013; 68(6): 937-943
17. Muller DC, Giles GG, Sinclair R., et al. Age-dependent associations between androgenetic alopecia and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2013; 22(2): 209-215
18. Zhou CK, Pfeiffer RM, Cleary SD., et al. Relationship between male pattern baldness and the risk of aggressive prostate cancer: an analysis of the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol. 2015; 33(5): 419-425
19. Zhou CK, Littman AJ, Levine PH., et al. Male pattern baldness in relation to prostate cancer risks: an analysis in the VITamins and lifestyle (VITAL) cohort study. Prostate. 2015; 75(4): 415-423
20. Hawk E, Breslow RA, Graubard BI. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev. 2000; 9(5): 523-527
21. Landis JR, Lepkowski JM, Eklund SA., et al. A statistical methodology for analyzing data from a complex survey: the first National Health and Nutrition Examination Survey. Vital Health Stat 2. 1982; (92): 1-52
22. Ingram DD, Makuc DM. Statistical issues in analyzing the NHANES I Epidemiologic Followup Study. Series 2: data evaluation and methods research. Vital Health Stat 2. 1994; (121): 1-30
23. Johnson MT, Roberts J. Skin conditions and related need for medical care among persons 1-74 years. United States, 1971-1974. Vital Health Stat 11. 1978; (212): i-v, 1-72
24. Ford ES, Freedman DS, Byers T. Baldness and ischemic heart disease in a national sample of men. Am J Epidemiol. 1996; 143(7): 651-657
25. Cox CS, Mussolino ME, Rothwell ST., et al. Plan and operation of the NHANES I Epidemiologic Followup Study, 1992. Vital Health Stat 1. 1997; (35): 1-231
26. National Center for Health Statistics, Office of Analysis and Epidemiology. The NHANES I Epidemiologic Follow-up Study (NHEFS) Linked Mortality File. Mortality follow-up through 2006: matching methodology. Hyattsville, MD. http: //www.cdc. gov/nchs/data/datalinkage/matching-methodology-nhefs-final. pdf. Published September 2009. Accessed July 3, 2014
27. National Center for Health Statistics. NHANES I Epidemiologic Follow-up Survey (NHEFS) calibration sample for NDI matching methodology. Hyattsville, MD. http: //www. cdc.gov/nchs/data/datalinkage/mort-calibration-study.pdf. Updated September 17, 2009. Accessed July 3, 2014
28. World Health Organization. Manual of the international statistical classification of diseases, injuries, and causes of death: based on the recommendations of the ninth Revision Conference, and adopted by the twenty-ninth World Health Assembly, Volume 1. Geneva, Switzerland: World Health Organization; 1975
29. Anderson RN, Miniño AM, Hoyert DL., et al. Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. Natl Vital Stat Rep. 2001; 49(2): 1-32
30. Korn EL, Graubard BI. Epidemiologic studies utilizing surveys: accounting for the sampling design. Am J Public Health. 1991; 81(9): 1166-1173
31. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997; 145(1): 72-80
32. Giles GG, Severi G, Sinclair R., et al. Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. Cancer Epidemiol Biomarkers Prev. 2002; 11(6): 549-553
33. Hoyert DL, Xu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep. 2012; 61(6): 1-51
34. Arias-Santiago S, Gutiérrez-Salmerón MT, Castellote-Caballero L., et al. Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study. J Am Acad Dermatol. 2010; 63(3): 420-429
35. Yamada T, Hara K, Umematsu H., et al. Male pattern baldness and its association with coronary heart disease: a meta-Analysis. BMJ Open. 2013; 3(4): e002537
36. Greenwald P, Damon A, Kirmss V., et al. Physical and demographic features of men before developing cancer of the prostate. J Natl Cancer Inst. 1974; 53(2): 341-346
37. Demark-WahnefriedW, Lesko SM, Conaway MR., et al. Serum androgens: associations with prostate cancer risk and hair patterning. J Androl. 1997; 18(5): 495-500
38. Hsieh CC, Thanos A, Mitropoulos D., et al. Risk factors for prostate cancer: a case-control study in Greece. Int J Cancer. 1999; 80(5): 699-703
39. Denmark-Wahnefried W, Schildkraut JM, Thompson D., et al. Early onset baldness and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2000; 9(3): 325-328
40. Faydaci G, Bilal E, Necmettin P., et al. Baldness, benign prostate hyperplasia, prostate cancer and androgen levels. Aging Male. 2008; 11(4): 189-192
41. Cremers RG, Aben KK, Vermeulen SH., et al. Androgenic alopecia is not useful as an indicator of men at high risk of prostate cancer. Eur J Cancer. 2010; 46(18): 3294-3299
42. Wright JL, Page ST, Lin DW., et al. Male pattern baldness and prostate cancer risk in a population-based case-control study. Cancer Epidemiol. 2010; 34(2): 131-135
43. Yassa M, Saliou M, De Rycke Y., et al. Male pattern baldness and the risk of prostate cancer. Ann Oncol. 2011; 22(8): 1824-1827
44. Thomas JA, Antonelli JA, Banez LL., et al. Androgenetic alopecia at various ages and prostate cancer risk in an equal-Access multiethnic case-control series of veterans. Cancer Causes Control. 2013; 24(5): 1045-1052
45. Marks LS. 5alpha-reductase: history and clinical importance. Rev Urol. 2004; (6 suppl 9): S11-S21
46. Brinkmann AO. Molecular basis of androgen insensitivity. Mol Cell Endocrinol. 2001; 179(1-2): 105-109
47. Patterson MN, McPhaul MJ, Hughes IA. Androgen insensitivity syndrome. Baillieres Clin Endocrinol Metab. 1994; 8(2): 379-404
48. Schweikert HU, Wilson JD. Regulation of human hair growth by steroid hormones. II. Androstenedione metabolism in isolated hairs. J Clin Endocrinol Metab. 1974; 39(6): 1012-1019
49. Bang HJ, Yang YJ, Lho DS., et al. Comparative studies on level of androgens in hair and plasma with premature male-pattern baldness. J Dermatol Sci. 2004; 34(1): 11-16
50. Huggins C, Stevens RE Jr, Hodges CV., et al. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941; 43(2): 209-223
51. Sutcliffe S, Colditz GA. Prostate cancer: is it time to expand the research focus to early-life exposures? Nat Rev Cancer. 2013; 13(3): 208-518
52. Zeigler-Johnson C, Morales KH, Spangler E., et al. Relationship of early-onset baldness to prostate cancer in African-American men. Cancer Epidemiol Biomarkers Prev. 2013; 22(4): 589-596
53. Penson DF, Albertsen PC, Nelson PS., et al. Determining cause of death in prostate cancer: Are death certificates valid? J Natl Cancer Inst. 2001; 93(23): 1822-1823
54. Albertsen PC, Walters S, Hanley JA. A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. J Urol. 2000; 163(2): 519-523
55. Andriole GL, Crawford ED, Grubb RL 3rd., et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104(2): 125-132